Filing Flows › Comparisons › NBIX vs HALO
Neurocrine Biosciences vs Halozyme Therapeutics: NBIX and HALO compared
Neurocrine Biosciences is the larger company: $1.1B of revenue in its latest quarter (Q3 2026) against $493M for Halozyme Therapeutics (Q3 2026). Neurocrine Biosciences is growing faster (+41% against +39% a year earlier). Halozyme Therapeutics is more profitable, with an operating margin of 59.8% against 29.5%.
Where the money goes: NBIX and HALO
Neurocrine Biosciences (NBIX) · Q3 2026
Neurocrine Biosciences, Q3 2026: revenue $1.1B (+41% year over year), operating margin 29.5%, net earnings $206M, operating cash flow $395M. The chart follows the revenue to costs, profit and cash.
Halozyme Therapeutics (HALO) · Q3 2026
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
| Neurocrine Biosciences (NBIX) | Halozyme Therapeutics (HALO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.1B | $493M |
| Revenue growth, Y/Y | +41% | +39% |
| Operating margin | 29.5% | 59.8% |
| Net earnings | $206M | $247M |
| Net margin | 18.4% | 50.1% |
| Operating cash flow | $395M | $258M |
| Free cash flow | $384M | $255M |
| Market value | $17.3B | $12.7B |
| P/E | 24.4× | 26.2× |
| Analysts’ mean target | $208.11 | $109.67 |
Where the revenue comes from
Halozyme Therapeutics
- Royalties: $341M (69%)
- Product sales, net: $137M (28%)
- Revenues under collaborative agreements: $14.6M (3%)
Questions
Which is bigger, Neurocrine Biosciences or Halozyme Therapeutics?
Neurocrine Biosciences is the larger company: $1.1B of revenue in its latest quarter (Q3 2026) against $493M for Halozyme Therapeutics (Q3 2026).
Is Neurocrine Biosciences or Halozyme Therapeutics growing faster?
Neurocrine Biosciences is growing faster (+41% against +39% a year earlier).
Which is more profitable, Neurocrine Biosciences or Halozyme Therapeutics?
Halozyme Therapeutics is more profitable, with an operating margin of 59.8% against 29.5%.
More: Neurocrine Biosciences earnings · how Neurocrine Biosciences makes money · Halozyme Therapeutics earnings · how Halozyme Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.